Novo Nordisk A/S
$ 43.97
2.71%
11 Jun - close price
- Market Cap 186,861,847,000 USD
- Current Price $ 43.97
- High / Low $ 44.11 / 42.95
- Stock P/E 9.90
- Book Value 7.10
- EPS 4.26
- Next Earning Report 2026-08-05
- Dividend Per Share $11.70
- Dividend Yield 4.27 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 0.71 %
- 52 Week High 77.68
- 52 Week Low 34.58
About
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Analyst Target Price
$47.21
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-03 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-01-31 | 2023-11-02 | 2023-08-10 |
| Reported EPS | 6.63 | 6.04 | 4.5 | 5.96 | 6.53 | 6.34 | 6.12 | 0.66 | 0.83 | 0.71 | 0.73 | 0.67 |
| Estimated EPS | 6.96 | 5.9 | 4.24 | 6 | 6.07 | 6.12 | 5.92 | 0.7366 | 0.77 | 0.66 | 0.69 | 0.63 |
| Surprise | -0.33 | 0.14 | 0.26 | -0.04 | 0.46 | 0.22 | 0.2 | -0.0766 | 0.06 | 0.05 | 0.04 | 0.04 |
| Surprise Percentage | -4.7414% | 2.3729% | 6.1321% | -0.6667% | 7.5783% | 3.5948% | 3.3784% | -10.3991% | 7.7922% | 7.5758% | 5.7971% | 6.3492% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 5.2 |
| Currency | DKK |
Previous Dividend Records
| Apr 2026 | Aug 2025 | Apr 2025 | Aug 2024 | Apr 2024 | Aug 2023 | Apr 2023 | Aug 2022 | Apr 2022 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-08 | 2025-08-26 | 2025-04-08 | 2024-08-26 | 2024-04-02 | 2023-08-29 | 2023-04-04 | 2022-08-23 | 2022-04-05 | None |
| Amount | $1.217376 | $0.584816 | $1.099206 | $0.5169016 | $0.92985 | $0.8835613 | $1.1887415 | $0.5835507 | $1.0360282 | $0.5570941 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVO
2026-06-11 18:58:00
Eli Lilly and Novo Nordisk are in a fierce competition for obesity drug market supremacy, with their Q1 2026 results showing divergent paths. Lilly experienced significant revenue growth and raised guidance, driven by the success of Mounjaro and Zepbound, and the FDA approval of its new oral GLP-1 pill, Foundayo. In contrast, Novo Nordisk reported a sales decline, is cutting 9,000 jobs, and faces challenges with its existing portfolio despite the launch of its own Wegovy pill.
2026-06-11 17:39:58
Novo Nordisk has secured approval in the UK for its oral Wegovy (semaglutide) formulation, marking a significant step in the weight-loss market. This approval by the MHRA provides an alternative to injectable GLP-1 drugs and positions Novo Nordisk ahead of Eli Lilly's rival oral therapy, Foundayo, in the UK. The drug is approved for adults with a BMI of 30 or above, or those overweight with a BMI between 27 and 30 and at least one weight-related comorbidity, though it still awaits NICE appraisal for NHS availability.
2026-06-11 15:45:00
Novo Nordisk announced a security incident where patient data from some clinical trials was copied externally without authorization. The company has launched an investigation with cybersecurity experts and is in contact with authorities. While the data includes patient ID, year of birth, sex, and health information, Novo Nordisk believes it's not directly linked to specific individuals and does not pose immediate risks to patients, although certain internal IT systems have been taken offline.
2026-06-11 15:40:07
Novo Nordisk announced that its Wegovy pill has been approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). This oral glucagon-like peptide-1 receptor agonist is licensed for weight management in adults with obesity or overweight and at least one weight-related condition. The approval offers a new, non-injectable alternative for adults and is based on data from the OASIS 4 phase 3 clinical trial.
2026-06-11 10:39:58
Novo Nordisk CEO Mike Doustdar reflects on his pivotal first year, expressing increased optimism despite initial hurdles. He highlights the successful launch of oral Wegovy, the company's focus on holistic metabolic treatments, and the resolution of supply issues for its GLP-1 products. Doustdar, formerly leading ex-U.S. operations, emphasizes his commercial background and patient-centric approach as crucial for Novo Nordisk's competitiveness in the rapidly evolving obesity market.
2026-06-10 15:10:45
Novo Nordisk's Chief Scientific Officer, Martin Holst Lange, believes it is too early to determine whether Novo's CagriSema or Eli Lilly's retatrutide is the superior next-generation obesity drug, despite some early comparisons favoring Lilly's offering. While acknowledging retatrutide's impressive weight loss data, Lange emphasized that Novo has several other pipeline assets that could prove competitive, and that factors beyond just weight loss, such as tolerability and comorbidity treatment, will become increasingly important. Novo expects even higher weight loss from CagriSema's ongoing Redefine 11 trial, and highlights its strong glycemic control in Type 2 diabetes.
